Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.47 |
| ▸ | DRD4 | P21917 | 15/20 | 0.47 |
| ▸ | DRD3 | P35462 | 15/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25564130 | 0.85 | DRD2 (0.50) | DRD2DRD4DRD3HSD11B1OPRM1 | |
| SCHEMBL25564223 | 0.84 | DRD2 (0.49) | DRD2DRD4DRD3HSD11B1OPRM1 | |
| SCHEMBL25564307 | 0.84 | DRD2 (0.49) | DRD2DRD4DRD3HSD11B1OPRM1 | |
| SCHEMBL25564309 | 0.84 | DRD2 (0.49) | DRD2DRD4DRD3HSD11B1OPRM1 | |
| SCHEMBL11823191 | 0.83 | KCNA3 (0.44) | HSD11B1OPRM1 | |
| SCHEMBL6889536 | 0.80 | LIPG (0.42) | DRD2HSD11B1OPRM1 | |
| SCHEMBL25564200 | 0.77 | DRD2 (0.44) | DRD2DRD4DRD3HSD11B1OPRM1 | |
| SCHEMBL25564201 | 0.76 | DRD2 (0.43) | DRD2DRD4DRD3HSD11B1 | |
| SCHEMBL11793808 | 0.76 | OPRM1 (0.39) | HSD11B1OPRM1 | |
| SCHEMBL25564194 | 0.76 | DRD2 (0.43) | DRD2DRD4DRD3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414813-B1 | 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES MALARIA VENTURE MMV (CH) | 2006-09-13 | — | — | EP | disclosed |
| US-6906205-B2 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2005-06-14 | — | — | US | disclosed |
| US-20040186168-A1 | Such as spiroadamantane on one side and 4-substituted spiro-cyclohexyl on other side; structurally simple, nontoxic, easy synthesis, potent parasiticides | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2004-09-23 | — | — | US | disclosed |
| EP-1414813-A1 | 1,2,4-TRIOXOLANE ANTIMALARIALS | Medicines for Malaria Venture (CH) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003000676-A1 | 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE (CH) | 2003-01-03 | — | — | WO | disclosed |
| US-6486199-B1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURE MMV INTERNATIONAL CENTRE COINTRIN (CH) | 2002-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186168-A1 | Such as spiroadamantane on one side and 4-substituted spiro-cyclohexyl on other side; structurally simple, nontoxic, easy synthesis, potent parasiticides | DHODH, SQLE, SULT1E1 | DRD2 1341/4885DRD4 1043/4885DRD3 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.